Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800)
South Korea · Delayed Price · Currency is KRW 2,995.00
-140.00 (-4.47%)
At close: Apr 9, 2026
Vivozon Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 59,343 | 87,601 | 71,318 | 51,564 | 57,560 |
Other Revenue | - | -0 | - | - | -0 |
| 59,343 | 87,601 | 71,318 | 51,564 | 57,560 | |
Revenue Growth (YoY) | -32.26% | 22.83% | 38.31% | -10.42% | 32.04% |
Cost of Revenue | 35,159 | 42,194 | 39,997 | 30,128 | 37,921 |
Gross Profit | 24,184 | 45,407 | 31,321 | 21,437 | 19,639 |
Selling, General & Admin | 38,360 | 37,111 | 25,082 | 23,031 | 28,627 |
Research & Development | 3,333 | 3,572 | 2,541 | 1,927 | 3,935 |
Amortization of Goodwill & Intangibles | 1,122 | 965.98 | 783.6 | 971.82 | 2,880 |
Operating Expenses | 43,350 | 47,208 | 26,611 | 31,243 | 39,253 |
Operating Income | -19,166 | -1,800 | 4,709 | -9,806 | -19,615 |
Interest Expense | -2,203 | -2,254 | -2,904 | -5,271 | -7,297 |
Interest & Investment Income | 197.46 | 170.39 | 345.14 | 840.79 | 909.59 |
Earnings From Equity Investments | -4,797 | -1,470 | -2,821 | - | -691.35 |
Currency Exchange Gain (Loss) | -23.49 | -58.49 | -6.07 | 125.03 | 999.14 |
Other Non Operating Income (Expenses) | 296.03 | -4,160 | -43.59 | -940 | -402.96 |
EBT Excluding Unusual Items | -25,695 | -9,572 | -720.44 | -15,051 | -26,097 |
Gain (Loss) on Sale of Investments | -1,744 | 7.32 | -812.22 | -4,842 | 69.4 |
Gain (Loss) on Sale of Assets | -89.46 | 76.21 | -596.57 | -102.92 | -229.9 |
Asset Writedown | -4,748 | -1,054 | -29.21 | -5,252 | -49,590 |
Other Unusual Items | - | - | - | -92.74 | - |
Pretax Income | -32,277 | -10,543 | -2,158 | -25,342 | -75,848 |
Income Tax Expense | 48.61 | 123.68 | 55.27 | 1,509 | -4,833 |
Earnings From Continuing Operations | -32,326 | -10,666 | -2,214 | -26,851 | -71,015 |
Earnings From Discontinued Operations | -98.13 | 684.46 | -1,143 | -13,827 | - |
Net Income to Company | -32,424 | -9,982 | -3,357 | -40,677 | -71,015 |
Minority Interest in Earnings | - | - | - | 771.55 | 1,558 |
Net Income | -32,424 | -9,982 | -3,357 | -39,906 | -69,457 |
Net Income to Common | -32,424 | -9,982 | -3,357 | -39,906 | -69,457 |
Shares Outstanding (Basic) | 50 | 48 | 48 | 44 | 33 |
Shares Outstanding (Diluted) | 50 | 48 | 48 | 44 | 33 |
Shares Change (YoY) | 3.65% | 0.09% | 9.69% | 33.41% | 24.52% |
EPS (Basic) | -655.00 | -209.00 | -70.35 | -917.27 | -2129.90 |
EPS (Diluted) | -655.00 | -209.00 | -70.35 | -917.27 | -2130.00 |
Free Cash Flow | -8,281 | -2,719 | -1,532 | -9,814 | -27,608 |
Free Cash Flow Per Share | -167.28 | -56.93 | -32.10 | -225.59 | -846.59 |
Gross Margin | 40.75% | 51.83% | 43.92% | 41.57% | 34.12% |
Operating Margin | -32.30% | -2.05% | 6.60% | -19.02% | -34.08% |
Profit Margin | -54.64% | -11.39% | -4.71% | -77.39% | -120.67% |
Free Cash Flow Margin | -13.95% | -3.10% | -2.15% | -19.03% | -47.96% |
EBITDA | -14,738 | 1,764 | 7,937 | -6,162 | -14,062 |
EBITDA Margin | -24.83% | 2.01% | 11.13% | -11.95% | -24.43% |
D&A For EBITDA | 4,427 | 3,564 | 3,228 | 3,643 | 5,552 |
EBIT | -19,166 | -1,800 | 4,709 | -9,806 | -19,615 |
EBIT Margin | -32.30% | -2.05% | 6.60% | -19.02% | -34.08% |
Advertising Expenses | 789.45 | 343.73 | 617.32 | 1,688 | 4,419 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.